Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Elahere (mirvetuximab soravtansine-gynx)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie, Huadong Medicine, Takeda

Drug class:

Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A1 - Approval bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A1	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A1 - Approval bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Peritoneal Cancer	FOLR1 positive	Peritoneal Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Fallopian Tube Cancer	FOLR1 positive	Fallopian Tube Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Fallopian Tube Cancer	FOLR1 expression	Fallopian Tube Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Peritoneal Cancer	FOLR1 expression	Peritoneal Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Peritoneal Cancer	FOLR1 expression	Peritoneal Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Fallopian Tube Cancer	FOLR1 expression	Fallopian Tube Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 overexpression	Ovarian Cancer	FOLR1 overexpression	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials mirvetuximab soravtansine-gynx Sensitive : B	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials mirvetuximab soravtansine-gynx Sensitive : B
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials mirvetuximab soravtansine-gynx Sensitive : C3	mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 overexpression	Gastric Cancer	FOLR1 overexpression	Gastric Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials bevacizumab + mirvetuximab soravtansine-gynx Sensitive : C3	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials bevacizumab + mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 overexpression	Ovarian Cancer	FOLR1 overexpression	Ovarian Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials bevacizumab + mirvetuximab soravtansine-gynx Sensitive : C3	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials bevacizumab + mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3